Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Bison Capital Acquisition Corp (XYN) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/06/2020 15-15D Form 15-15D - Suspension of duty to report [Section 13 and 15(d)]:
07/06/2020 RW Form RW - Registration Withdrawal Request:
06/29/2020 8-K Quarterly results
06/29/2020 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/14/2020 8-K Other Events
05/14/2020 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/30/2020 8-K Other Events
03/27/2020 8-K Other Events
02/13/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/14/2019 10-Q Quarterly Report for the period ended September 30, 2019
09/27/2019 8-K Investor presentation
Docs: "Investor Presentation (September 2019)"
09/23/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma SHANGHAI, September 23, 2019 — Xynomic Pharmaceuticals Holdings, Inc. , a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration has granted Fast-Track designation to Xynomic’ s lead drug candidate abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma . Fast-Track is a designation by the FDA to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and fill an unmet medical need. According to the U.S. National Cancer Institute, FL is the most common indolent non-Hodgkin’ s lymphoma subtype in the U..."
09/20/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/13/2019 8-K Quarterly results
09/06/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Amended and Restated Securities Purchase Agreement by and among the Company and the Purchasers"
08/30/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 — Xynomic Pharmaceuticals Holdings, Inc. , a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead candidate abexinostat, an orally dosed, hydroxamic acid-based small molecule histone deacetylase inhibitor , in combination with Keytruda®, for the treatment of multiple solid tumors. The trial is being conducted at University of California, San Francisco. The interim data will also be presented at the 3rd World-China Immunotherapy & Gene Therapy Congress 2019 to be held in Beijing from August 30th to 31st, 2019. This Phase 1b trial explore..."
08/27/2019 8-K Submission of Matters to a Vote of Security Holders
08/16/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "About Xynomic Pharmaceuticals Holdings, Inc."
08/15/2019 10-Q Quarterly Report for the period ended June 30, 2019
08/14/2019 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/07/2019 8-K Quarterly results
08/06/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/01/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA RALEIGH, N.C. and SHANGHAI, August 1, 2019 — Xynomic Pharmaceuticals Holdings, Inc. , a clinical stage U.S.-China oncology drug development company, announced that it has filed an application with the U.S. Food and Drug Administration seeking Fast-Track designation for its drug candidate abexinostat as a monotherapy for the treatment of relapsed or refractory follicular lymphoma . Fast-Track designation is designed to aid in the development and expedite the review of drug candidates, which show promise in treating a serious or life-threatening disease, and address an unmet medical need. A drug candidate that receives Fast-Track designation is eligible for more frequent meetings and correspo..."
07/30/2019 8-K Quarterly results
07/26/2019 PRE 14A Form PRE 14A - Other preliminary proxy statements:
07/17/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
07/15/2019 D Form D - Notice of Exempt Offering of Securities:
07/11/2019 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
07/11/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Securities Purchase Agreement by and among the Company and the Purchasers",
"Form of Warrants"
07/05/2019 8-K/A Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "Unaudited Financial Statements of Xynomic Pharmaceuticals, Inc. as of March 31, 2019, and for the three months ended March 31, 2018 and 2019",
"Pro Forma Financial Statements as of March 31, 2019, and for the three months ended March 31, 2019"
06/21/2019 8-K Investor presentation
Docs: "Investor Presentation (June 2019)"
06/12/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer RALEIGH, N.C. and SHANGHAI, June 12, 2019 -- Xynomic Pharmaceuticals Holdings, Inc. , a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the U.S. Food and Drug Administration for its pan-PAF inhibitor XP-102 for the treatment of cancers. The FDA addressed Xynomic' questions related to CMC, nonclinical and clinical protocol, and provided valuable advice on overall clinical development plan to advance this drug candidate. Xynomic is on track to file this Investigational New Drug application in the second half of 2019. XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding t..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy